Bod Australia (ASX:BOD) completes successful study on new medicinal cannabis product – The Market Herald

Bod Australia (BOD) has seen positive results from its study into the safety and efficacy of a cannabigerol (CBG) dominant cannabis extract.
The study is part of the basis for the launch of a new medical cannabis product that will be sold under the company’s existing medicinal cannabis brand, MediCabilis CBG 50. The new product is expected to launch next month.
CBG is a non-intoxicating cannabinoid compound found in the cannabis plant. The extract has shown to be beneficial in the treatment of fibromyalgia, inflammatory bowel disease and irritable bowel syndrome (IBS) amongst others.
The study was completed over three months to assess the safety and efficacy of the drug in patients suffering from symptoms associated with fibromyalgia, inflammatory bowel disease and anxiety.
In the trial, 74 per cent of participants noticed improvements to their condition within two to four weeks of using MediCabilis CBG 50.
Trial data will be shared with doctors and approved prescribers in both Australia and the UK to help in the ongoing educational initiative undertaken by the company.
“The completion of this initiative has highlighted that MediCabilis CBG 50 is both safe
and effective for use across a range of new symptoms that our product has not been previously prescribed for,” CEO Jo Patterson said.
“The study will also allow Bod to explore the possibility of using its extract as an alternative treatment or all encompassing route for conditions that require a mix of surgery, medication and other routines.”
On the market this afternoon, BOD shares were in the grey and trading at 14 cents per share at 1:00 pm AEST.



Buy Weed In Australia

Articles: 148

Leave a Reply

Your email address will not be published.